<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683472</url>
  </required_header>
  <id_info>
    <org_study_id>1R41MH118130-01</org_study_id>
    <nct_id>NCT03683472</nct_id>
  </id_info>
  <brief_title>Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder</brief_title>
  <official_title>Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MindSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MindSciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to develop and adapt Unwinding Anxiety phone app specifically for
      individuals with generalized anxiety disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims are to (1) develop and refine Unwinding Anxiety for individuals with
      generalized anxiety disorder, (2) determine user engagement and acceptability as well as
      measure effect sizes of the program vs. treatment as usual, and (3) preliminarily test
      mechanisms of action. The knowledge gained will set the stage for a number of future studies
      related to further elucidating the mechanisms of mindfulness, and the clinical efficacy and
      utility of this type of training delivered via digital therapeutics in general. Specifically,
      this study will provide necessary variances for powering larger phase 2 studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">October 17, 2019</completion_date>
  <primary_completion_date type="Actual">October 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>UA Program engagement</measure>
    <time_frame>Two months</time_frame>
    <description>Number of modules completed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in worry</measure>
    <time_frame>Baseline, two months</time_frame>
    <description>Penn State Worry Questionnaire (PSWQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in non-reactivity &amp; awareness</measure>
    <time_frame>Baseline, two months</time_frame>
    <description>Five Facet Mindfulness Questionnaire - Non-Reactivity subscale (FFMQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UA Program Acceptability</measure>
    <time_frame>Two months</time_frame>
    <description>Net Promoter Score (NPS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in anxiety</measure>
    <time_frame>Baseline, two months</time_frame>
    <description>Generalized Anxiety Disorder - 7 items (GAD-7)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in self-regulation</measure>
    <time_frame>Baseline, two months</time_frame>
    <description>Multidimensional Assessment of Interoceptive Awareness (MAIA)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Treatment as usual (TAU)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Individuals will receive treatment as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU and Unwinding Anxiety Phone App</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry &quot;habit loops&quot; and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and &quot;ride out&quot; habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals &quot;unlearn&quot;/extinguish worry at a core mechanistic level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Unwinding Anxiety Phone App</intervention_name>
    <description>The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry &quot;habit loops&quot; and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and &quot;ride out&quot; habitual mind states that perpetuate and reinforce anxiety</description>
    <arm_group_label>TAU and Unwinding Anxiety Phone App</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Owns a smart phone

          -  GAD - 7 is equal to or greater than 10

        Exclusion Criteria:

          -  If using psychotropic medication - not on a stable dosage for at least 6 weeks

          -  Medical disorder of the severity that would interfere with ability to participate

          -  Not being fluent in English (due to instructions provided in English)

          -  As needed use (i.e. prn) of benzodiazepines

          -  Psychotic disorder,

          -  Previous MT (e.g. MBSR, other Claritas MindSciences training programs).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judson Brewer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brown University</investigator_affiliation>
    <investigator_full_name>Judson Brewer</investigator_full_name>
    <investigator_title>Director of Research &amp; Innovation</investigator_title>
  </responsible_party>
  <keyword>Anxiety, worry, mindfulness, meditation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT03683472/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

